Similar articles

• Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma.

  Tian J, Luo J, Zeng X, Ke C, Wang Y, Liu Z, Li L, Zhang Y, Hu Z, Yang C. Tian J, et al. J Immunother Cancer. 2024 Feb 14;12(2):e008226. doi: 10.1136/jitc-2023-008226. J Immunother Cancer. 2024. PMID: 38355278 Free PMC article.
• Targeting Oxidative Phosphorylation to Increase the Efficacy of Radio- and Immune-Combination Therapy.

  Boreel DF, Span PN, Heskamp S, Adema GJ, Bussink J. Boreel DF, et al. Clin Cancer Res. 2021 Jun 1;27(11):2970-2978. doi: 10.1158/1078-0432.CCR-20-3913. Epub 2021 Jan 8. Clin Cancer Res. 2021. PMID: 33419779 Review.
• Oxidative Phosphorylation-Related Signature Participates in Cancer Development, and PTPRG Overexpression Suppresses the Cancer Progression in Clear Cell Renal Cell Carcinoma.

  Huang L, Xie Y, Han W, Jiang S, Zeng L. Huang L, et al. J Immunol Res. 2022 Nov 10;2022:8300187. doi: 10.1155/2022/8300187. eCollection 2022. J Immunol Res. 2022. PMID: 36405010 Free PMC article.
• Identification of ferroptosis-related signature with potential implications in prognosis and immunotherapy of renal cell carcinoma.

  Liu L, Jin H, Dong M, Tian J, Li H, Liu Q, Chen Y, Zou Z. Liu L, et al. Apoptosis. 2022 Dec;27(11-12):946-960. doi: 10.1007/s10495-022-01766-5. Epub 2022 Aug 26. Apoptosis. 2022. PMID: 36028785
• Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.

  de Velasco G, Bex A, Albiges L, Powles T, Rini BI, Motzer RJ, Heng DYC, Escudier B. de Velasco G, et al. Eur Urol Oncol. 2019 Sep;2(5):505-514. doi: 10.1016/j.euo.2019.06.022. Epub 2019 Aug 1. Eur Urol Oncol. 2019. PMID: 31377308 Review.